ArticleThe Journal of urology2025
Defining Abnormal Prostate-Specific Antigen Values for Prostate Cancer Screening in the Spinal Cord Injury Population.
Article in The Journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurogenic lower urinary tract dysfunction in ageing men with spinal cord injury.Nature reviews. Urology · 2026Review
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
purposeMen with spinal cord injury (SCI) experience frequent urinary tract inflammation and manipulation as well as chronic hypogonadism, all of which may artifactually alter PSA values. Thus, established PSA reference ranges and age-adjusted values may not be accurate in this population. This study's objective was to use national Department of Veterans Affairs data to establish threshold values for PSA in the SCI population to guide decision-making in prostate cancer screening. MATERIALS AND
methodsAll PSA values in the national Department of Veterans Affairs system in men with SCI were collected between 1999 and 2019. Values collected before a diagnosis of SCI and after a diagnosis of prostate cancer were excluded. Determination of SCI was based on a list of International Classification of Diseases, 9th Revision and 10th Revision codes. Mixed-effect quantile regression was used to estimate percentile PSA values adjusted by age and time since SCI. These values were then compared with published values in the non-SCI population.
resultsA total of 34,899 male veterans with SCI were included in the analysis with a total of 240,131 PSA values. Using the best-fit model, age-adjusted PSA values for the 25th, 50th, 75th, and 95th percentiles were created. The 95th age-adjusted percentile values for PSA in the SCI population were 40 to 49 years: 2.5 ng/mL; 50 to 59 years: 2.6 ng/mL; 60 to 69 years: 2.6 ng/mL; and 70 to 79 years: 2.8 ng/mL.
conclusionsUsing a large, geographically diverse database, age-adjusted PSA values in the SCI population can be generated. While PSA values of the SCI population are comparable in younger men, as the SCI population ages, PSA fails to rise and stagnates at around 3 ng/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.